ACID REDUCER 75 MG
RANITIDINE (RANITIDINE HYDROCHLORIDE) : 75 MG · DIN 02230507 · APOTEX INC
Health Canada status: DORMANT
What is ACID REDUCER?
ACID REDUCER 75 MG contains RANITIDINE (RANITIDINE HYDROCHLORIDE) : 75 MG. It is listed in the Health Canada Drug Product Database under DIN 02230507, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 04-Aug-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is ACID REDUCER called?
Also recorded in Canada as: ZANTAC (US), ZANTAC (EU), ZANTAC (UK), RANITIDINE (GLOBAL), RANITIDINE (US), RANITIDINE (UK), RANITIDINE (JP), Zantac (GLOBAL).
The same molecule, RANITIDINE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| ZANTAC | Latin | Morocco, Saudi Arabia |
| EFITAC | Latin | Morocco |
| AZANTAC | Latin | Morocco |
| RANITIL | Latin | Morocco |
| ACICARE | Latin | Saudi Arabia |
| ACIDAC | Latin | Morocco |
| NORMACIDE | Latin | Morocco |
| RANIMAT | Latin | Morocco |
| APO-Ranitidine | Latin | Australia |
| PEP-RANI | Latin | Morocco |
| RANIMAX AC TABLET | Latin | Saudi Arabia |
| Ranit | Latin | South Africa |
| R-loc Injection | Latin | South Africa |
| Ranitidine Injection Pharma-Q | Latin | South Africa |
| Zantac Syrup | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02230507 |
|---|---|
| Brand name | ACID REDUCER |
| Generic / active ingredient | RANITIDINE (RANITIDINE HYDROCHLORIDE) : 75 MG |
| Manufacturer | APOTEX INC |
| Strength | 75 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A02BA02 RANITIDINE |
| AHFS class | 56:28.12 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 04-Aug-2017 |
| Original market date | 1999-02-08 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02230507 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2230507 |
| Brand name | ACID REDUCER |
| Active ingredient / INN | RANITIDINE (RANITIDINE HYDROCHLORIDE) : 75 MG |
| ATC code | A02BA02 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A02 |
| AHFS class | 56:28.12 |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| Biosimilar biologic | No |
| Market authorization holder | APOTEX INC |
Which pack is which?
| Strength on the label | 75 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code A02BA02 RANITIDINE. 5 of 96 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MAR-RANITIDINE | 150 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02443708 |
| MAR-RANITIDINE | 300 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02443716 |
| MAXIMUM STRENGTH ACID REDUCER WITHOUT PRESCRIPTION | 150 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02293471 |
| MINT-RANITIDINE | 150 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02526379 |
| MINT-RANITIDINE | 300 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02526387 |
| ACID REDUCER | 150 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | APPROVED | DIN 02291282 |
| ACID REDUCER | 150 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02400103 |
| ACID REDUCER | 150 MG | TABLET | APOTEX INC | DORMANT | DIN 02296160 |
| ACID REDUCER | 75 MG | TABLET | WESTCAN PHARMACEUTICALS LTD. | CANCELLED PRE MARKET | DIN 02240348 |
| ACID REDUCER | 75 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | DIN 02237829 |
Who else supplies RANITIDINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RANITIDINE appears in 4061 registered pack listings across 3 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does RANITIDINE cost around the world?
RANITIDINE is listed on 4 national price registers Nexara tracks, across 136 pack listings published on 4 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Saudi Arabia | public | 40 | 58 | 01 Sep 2026 |
| South Africa | single exit price | 31 | 42 | 01 Sep 2026 |
| Morocco | PPV (public price) | 8 | 32 | 05 Sep 2026 |
| Australia | ex-manufacturer | 3 | 4 | 08 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.